Provided by Tiger Fintech (Singapore) Pte. Ltd.

MiNK Therapeutics, Inc.

7.57
+0.32294.45%
Post-market: 7.49-0.0829-1.09%16:04 EDT
Volume:879.00
Turnover:6.51K
Market Cap:30.18M
PE:-3.03
High:7.57
Open:7.57
Low:7.57
Close:7.25
Loading ...

Press Release: MiNK Therapeutics Announces Virtual Annual Shareholders Meeting

Dow Jones
·
11 Jun

MiNK Therapeutics Secures NIAID Grant to Advance Allo-iNKT Cell Therapy for GvHD Prevention in Collaboration with University of Wisconsin

Reuters
·
02 Jun

Mink Therapeutics Awarded Prestigious Niaid Grant to Advance Allo-Inkt Cell Therapy for Prevention of Gvhd in Stem Cell Transplant Patients

THOMSON REUTERS
·
02 Jun

MiNK Therapeutics: Promising Clinical Trials and Strategic Plans Justify Buy Rating

TIPRANKS
·
15 May

Mink Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
15 May

MiNK Therapeutics Q1 EPS $(0.70) Beats $(0.71) Estimate

Benzinga
·
15 May

MiNK Therapeutics Reports Q1 2025 Results: Net Loss Decreases to $2.8 Million, EPS Improves to $(0.70)

Reuters
·
15 May

Mink Therapeutics Reports Q1 2025 Results and Highlights Clinical & Strategic Progress

THOMSON REUTERS
·
15 May

Press Release: MiNK Therapeutics Reports Q1 2025 Results and Highlights Clinical & Strategic Progress

Dow Jones
·
15 May

MiNK Therapeutics to Provide Corporate Update and First Quarter 2025 Financial Report

GlobeNewswire
·
06 May

MiNK Therapeutics Inc (INKT) Q4 2024 Earnings Call Highlights: Strategic Advances Amid ...

GuruFocus.com
·
19 Mar

MiNK Therapeutics Reports 2024 Progress and Financials

TIPRANKS
·
19 Mar

Q4 2024 Mink Therapeutics Inc Earnings Call

Thomson Reuters StreetEvents
·
19 Mar

Buy Rating Affirmed for MiNK Therapeutics Amid Promising Clinical Developments and Strategic Expansion

TIPRANKS
·
19 Mar

Promising Clinical Data and Strategic Initiatives Drive Buy Rating for MiNK Therapeutics

TIPRANKS
·
18 Mar

Mink Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
18 Mar

MiNK Therapeutics Q4 2024 GAAP EPS $(0.62) Misses $(0.50) Estimate

Benzinga
·
18 Mar

Press Release: MiNK Therapeutics Reports Fourth Quarter & Full Year 2024 Results and Highlights Business Progress

Dow Jones
·
18 Mar

Mink Therapeutics Inc expected to post a loss of 50 cents a share - Earnings Preview

Reuters
·
14 Mar

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
14 Mar